Document Detail


Erectile dysfunction drugs and risk of anterior ischaemic optic neuropathy: casual or causal association?
MedLine Citation:
PMID:  17947271     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Phosphodiesterase type 5 (PDE5) inhibitor drugs for erectile dysfunction have revolutionised the treatment of male sexual dysfunction and are among the best selling drugs worldwide. Several cases of non-arteritic anterior ischaemic optic neuropathy (NAION) have been reported since 2005 in users of these agents. NAION is a sudden irreversible cause of visual loss with a poorly understood aetiology that affects up to 10 adults per 100,000 each year. Following a series of such case reports, WHO and FDA have labelled the association between use of PDE5 inhibitors and risk of NAION as "possibly" causal. There have been several recent studies of this association, including a rechallenge case report and a large managed care database study. However, the inability to confirm or refute claims of an association between NAION and EDD is generating clinical and regulatory uncertainty. Questions surrounding use of PDE5 inhibitors and risk of NAION highlight weaknesses in current systems used to identify and evaluate uncommon adverse effects of medication use. This paper reviews all the recent evidence on PDE5 inhibitors and the risk of NAION.
Authors:
Helen V Danesh-Meyer; Leonard A Levin
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  The British journal of ophthalmology     Volume:  91     ISSN:  0007-1161     ISO Abbreviation:  Br J Ophthalmol     Publication Date:  2007 Nov 
Date Detail:
Created Date:  2007-10-19     Completed Date:  2007-11-20     Revised Date:  2013-06-06    
Medline Journal Info:
Nlm Unique ID:  0421041     Medline TA:  Br J Ophthalmol     Country:  England    
Other Details:
Languages:  eng     Pagination:  1551-5     Citation Subset:  IM    
Affiliation:
Department of Ophthalmology, University of Auckland, Private Bag 92019, Auckland New Zealand. h.daneshmeyer@auckland.ac.nz
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
3',5'-Cyclic-GMP Phosphodiesterases / antagonists & inhibitors
Adult
Aged
Epidemiologic Methods
Erectile Dysfunction / drug therapy*
Humans
Male
Middle Aged
Optic Neuropathy, Ischemic / chemically induced*
Phosphodiesterase Inhibitors / adverse effects*
Product Surveillance, Postmarketing
Vasodilator Agents / adverse effects*
Chemical
Reg. No./Substance:
0/Phosphodiesterase Inhibitors; 0/Vasodilator Agents; EC 3.1.4.35/3',5'-Cyclic-GMP Phosphodiesterases
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Technique of amniotic membrane transplant dressing in the management of acute Stevens-Johnson syndro...
Next Document:  Diagnostic trends in autistic spectrum disorders in the South Wales valleys.